{"id":"https://openalex.org/W7225757272","doi":"https://doi.org/10.25251/31rhrb86","title":"Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis","display_name":"Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225757272","doi":"https://doi.org/10.25251/31rhrb86"},"language":"en","primary_location":{"id":"doi:10.25251/31rhrb86","doi":"https://doi.org/10.25251/31rhrb86","is_oa":true,"landing_page_url":"https://doi.org/10.25251/31rhrb86","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/31rhrb86","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017733613","display_name":"Oza Vikash","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vikash Oza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160193017","display_name":"Alan Irvine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alan Irvine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041787107","display_name":"Vivian T. Laquer","orcid":"https://orcid.org/0000-0001-8860-0876","observed_orcids":["https://orcid.org/0000-0001-8860-0876","https://orcid.org/0009-0004-7554-8684"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vivian Laquer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043201259","display_name":"Peter Lio","orcid":"https://orcid.org/0000-0001-7600-0152","observed_orcids":["https://orcid.org/0000-0001-7600-0152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Lio","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022959615","display_name":"Elizabeth A. Swanson","orcid":"https://orcid.org/0000-0002-6681-6294","observed_orcids":["https://orcid.org/0000-0002-6681-6294","https://orcid.org/0009-0003-7847-453X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth Swanson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008286260","display_name":"Kim Alexander Papp","orcid":"https://orcid.org/0000-0001-9557-3642","observed_orcids":["https://orcid.org/0000-0001-9557-3642"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kim Papp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093252455","display_name":"Louise Ann DeLuca-Carter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Louise DeLuca-Carter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5130789174","display_name":"Heidi Crane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Heidi Crane","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003050074","display_name":"Hany Elmaraghy","orcid":"https://orcid.org/0000-0003-3552-9345","observed_orcids":["https://orcid.org/0000-0003-3552-9345"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hany Elmaraghy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128888760","display_name":"Yuxin Ding","orcid":"https://orcid.org/0009-0006-5190-4239","observed_orcids":["https://orcid.org/0009-0006-5190-4239"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yuxin Ding","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093252176","display_name":"Meihua Qiao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meihua Qiao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5161412137","display_name":"Amy Susan Paller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amy Susan Paller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s834","last_page":"s834"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6617000102996826},{"id":"https://openalex.org/C58041806","wikidata":"https://www.wikidata.org/wiki/Q1660484","display_name":"Imputation (statistics)","level":3,"score":0.5691999793052673},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.4643999934196472},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.38929998874664307},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.37290000915527344},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3546999990940094},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.3156000077724457},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.2800999879837036},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.27459999918937683},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.24400000274181366}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/31rhrb86","doi":"https://doi.org/10.25251/31rhrb86","is_oa":true,"landing_page_url":"https://doi.org/10.25251/31rhrb86","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/31rhrb86","doi":"https://doi.org/10.25251/31rhrb86","is_oa":true,"landing_page_url":"https://doi.org/10.25251/31rhrb86","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W4361263483"],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"In":[1,70,233,300],"the":[2,13,34,55,63,71,101,131,140,273,330],"maintenance":[3,22,68,260,366,384],"periods":[4],"of":[5,29,91,111,193,215,223,282,313,380],"ADvocate1":[6],"and":[7,17,25,160,205,210,241,250,280,284,291,293,326,332,338,348,382],"ADvocate2,":[8],"efficacy":[9],"was":[10,119,230,245],"consistent":[11,84],"between":[12],"every":[14,18,360],"2":[15],"weeks":[16,20,110,364],"4":[19,361],"(Q4W)":[21],"dosing":[23,44],"regimens,":[24],"a":[26,67,105,120,237],"high":[27,307],"proportion":[28],"Week":[30,220,310],"16":[31],"responders":[32],"in":[33,48,100,139,202,272,329,370],"lebrikizumab":[35,181,387],"withdrawal":[36],"arm":[37],"exhibited":[38],"durable":[39,106,368],"efficacy,":[40],"suggesting":[41],"less":[42],"frequent":[43],"could":[45],"maintain":[46],"effectiveness":[47],"atopic":[49],"dermatitis":[50],"(AD).":[51],"An":[52],"extension":[53,74,103,118,172,277,309],"to":[54,80,177,375,393],"ADjoin":[56,73,102,117,134,171],"long-term":[57,133],"study":[58,122,135,155,168,200],"(ADjoin":[59],"extension)":[60],"subsequently":[61],"evaluated":[62],"Q8W":[64,76,114,285,333,351,383],"interval":[65],"as":[66,365],"regimen.":[69,261],"overall":[72],"population,":[75],"has":[77],"been":[78],"reported":[79],"provide":[81,388],"clinical":[82],"responses":[83],"with":[85,126,373,390],"Q4W":[86,112,184,283,331,347,381],"dosing.":[87,115],"As":[88],"approximately":[89],"10%":[90],"adolescents":[92,99,150,397],"have":[93],"AD,":[94],"this":[95,234],"analysis":[96],"describes":[97],"whether":[98],"had":[104,129,287,295],"response":[107,304,369],"over":[108],"32":[109],"or":[113,149,185,362],"Methods:":[116],"32-week":[121,274],"that":[123],"enrolled":[124,271],"patients":[125,174,194,224,266,286,314,352,372],"AD":[127,162,229,355],"who":[128,318],"completed":[130],"100-week":[132],"(NCT04392154)":[136],"after":[137],"participation":[138],"parent":[141,154,167,199],"studies.":[142],"Key":[143],"eligibility":[144],"criteria":[145],"included":[146],"being":[147],"adults":[148],"(\u226512\u2013<18":[151],"years":[152],"at":[153,166,219],"baseline;":[156],"weight":[157],"\u226540":[158],"kg)":[159],"moderate-to-severe":[161],"for":[163,228,247,386,396],"\u22651":[164],"year":[165],"entry.":[169],"At":[170,276],"baseline,":[173,278],"were":[175,191,255,323],"re-randomized":[176],"receive":[178],"open":[179],"label":[180],"250":[182],"mg":[183],"Q8W.":[186],"The":[187,378],"two":[188],"primary":[189],"endpoints":[190],"percentages":[192,312],"achieving":[195],"\u226575%":[196],"improvement":[197],"(from":[198],"baseline)":[201],"Eczema":[203],"Area":[204],"Severity":[206],"Index":[207],"(EASI":[208],"75)":[209],"Investigator\u2019s":[211],"Global":[212],"Assessment":[213],"score":[214],"0/1":[216],"(IGA":[217],"0,1)":[218],"32.":[221],"Proportion":[222],"requiring":[225],"concomitant":[226,354],"treatment":[227,395],"also":[231],"reported.":[232],"post-hoc":[235],"analysis,":[236],"combined":[238],"non-responder":[239],"imputation":[240,243],"multiple":[242],"method":[244],"used":[246],"intercurrent":[248],"events":[249],"missing":[251],"data.":[252],"Efficacy":[253],"outcomes":[254],"summarized":[256],"descriptively":[257],"within":[258],"each":[259],"Results:":[262],"Overall,":[263],"40":[264],"adolescent":[265,371],"(Q4W,":[267],"N=22;":[268],"Q8W,":[269],"N=18)":[270],"extension.":[275],"86.4%":[279],"83.3%":[281],"an":[288,296,320,342],"EASI":[289,321],"75":[290,322],"68.2%":[292,336],"66.7%":[294],"IGA":[297,343],"(0,1),":[298],"respectively.":[299],"both":[301],"arms,":[302],"mean":[303],"rates":[305],"remained":[306],"through":[308],"32:":[311],"(95%":[315],"confidence":[316],"interval)":[317],"met":[319,341],"81.8%":[324],"(65.7%-97.9%)":[325],"70.9%":[327],"(49.4%-92.4%)":[328],"groups,":[334],"respectively;":[335],"(48.7%-87.6%)":[337],"63.1%":[339],"(40.2%-86.0%)":[340],"(0,1).":[344],"Six":[345],"(27.3%)":[346],"seven":[349],"(38.9%)":[350],"required":[353],"treatment.":[356],"Conclusions:":[357],"Lebrikizumab":[358],"dosed":[359],"8":[363],"provides":[367],"moderate":[374],"severe":[376],"AD.":[377],"availability":[379],"regimens":[385],"clinicians":[389],"greater":[391],"flexibility":[392],"individualize":[394]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}